Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Under no circumstances this document is to be used or considered as an offer to sell, or a solicitation of any offer to buy, any security. While information contained herein has been obtained from ...

The US investment firm is aiming to fetch a valuation of at least US$2bil for the company in a deal. — Bloomberg NEW YORK: Private equity firm TPG Inc is considering options for APM Monaco, including ...

As of March 18, 2026, Aptorum Group Limited had a $6.4 million market capitalization, putting it in the 4th percentile of companies in the Biotechnology industry. Aptorum Group Limited does not have a ...